Antisense Oligonucleotides for Precise MECP2 Expression Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurological disorders associated with MECP2 overexpression, such as MECP2 duplication syndrome and Rett Syndrome, are lacking effective options.
Innovation Solution
The use of modified antisense oligonucleotides that specifically target MECP2 mRNA and protein to modulate their expression levels, reducing MECP2 levels sufficiently to treat and prevent symptoms of MECP2 duplication syndrome without causing underexpression-related symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If MECP2 expression is increased to treat neurological disorders, then therapeutic benefit is improved, but risk of overexpression toxicity increases
Solution Approach 1:
The patent applies parameter changes by precisely controlling MECP2 expression levels through regulated promoter systems and inducible transcription mechanisms. The system allows dynamic adjustment of expression parameters (timing, level, duration) to achieve therapeutic benefit while avoiding the harmful threshold of overexpression toxicity.
Solution Approach 2:
The patent implements feedback control through cellular response monitoring mechanisms that detect MECP2 expression levels and adjust transcription accordingly. This feedback system prevents accumulation to toxic levels while maintaining sufficient expression for therapeutic effect, resolving the contradiction between benefit and toxicity.
2Reliability
If MECP2 expression is reduced to treat MECP2 duplication syndrome, then symptom amelioration is improved, but risk of causing Rett Syndrome increases
Solution Approach 1:
The patent uses parameter changes to precisely modulate MECP2 expression down to therapeutic ranges without crossing into underexpression territory. Through controlled reduction mechanisms, the system achieves symptom amelioration while maintaining expression levels above the harmful threshold for Rett Syndrome.
Solution Approach 2:
The patent applies partial action by reducing MECP2 expression only to the extent necessary for therapeutic benefit, rather than complete suppression. This controlled partial reduction achieves symptom amelioration while avoiding the excessive reduction that would cause Rett Syndrome.
3Ease of operation
If conventional treatments are used for MECP2-related disorders, then treatment simplicity is maintained, but therapeutic effectiveness deteriorates
Solution Approach 1:
The patent introduces an intermediary controlled expression system that mediates between the simplicity of conventional treatment administration and the complexity of achieving precise therapeutic effectiveness. The regulated promoter system acts as an intermediary mechanism that maintains ease of delivery while ensuring therapeutic efficacy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antisense oligonucleotides effectively reduce MECP2 levels, ameliorating symptoms of MECP2 duplication syndrome, including autism, intellectual disability, and epilepsy, while avoiding the onset of Rett Syndrome symptoms.
Implementation Method 1
antisense compounds are single-stranded antisense oligonucleotides
Data Source
AI summary
Disclosed herein are compounds and methods for decreasing MECP2 mRNA and protein expression. Such compounds and methods are useful to treat, prevent, or ameliorate MECP2 associated disorders and syndromes. Such MECP2 associated disorders include MECP2 duplication syndrome.